Current Report Filing (8-k)
24 Juni 2019 - 10:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 24, 2019
CATALENT, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36587
|
|
20-8737688
|
(State or other jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
|
|
14 Schoolhouse Road
Somerset, New Jersey
|
|
08873
|
(Address of registrants principal executive office)
|
|
(Zip code)
|
(732)
537-6200
(Registrants telephone number, including area code)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
symbols(s)
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
CTLT
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On June 24, 2019, Catalent, Inc. issued a press release announcing that its wholly owned subsidiary, Catalent Pharma Solutions, Inc., has priced a private
offering of $500.0 million aggregate principal amount of 5.00% senior unsecured notes due 2027 (the Notes) at par.
The sale of the Notes
is expected to be consummated on June 27, 2019, subject to customary closing conditions.
The full text of the press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
Catalent, Inc.
(Registrant)
|
|
|
By:
|
|
/s/ Steven L. Fasman
|
|
|
Steven L. Fasman
|
|
|
Senior Vice President, General Counsel
|
|
|
and Secretary
|
Date: June 24, 2019
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024